06887.HK
Sunshine Lake Pharma Co., Ltd.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 37.48
−2.55%Aug 31, 2026, 09:10 UTC
Sunshine Lake Pharma's first domestic insulin glargine received FDA approval and achieved commercial shipment in the United States, securing overseas orders exceeding 18 million units.
Source:Aug 25, 2026, 02:30 UTC
Sunshine Lake Pharma issued a profit warning, expecting a net loss of about 590 million RMB for the first half of 2026, an increase of about 540 million RMB compared to the same period last year.
Jul 21, 2026, 01:12 UTC
Sunshine Lake Pharma (06887.HK) repurchased 817,500 shares on the open market on July 20, 2026, for approximately HKD 26.3589 million, to be held as treasury shares.
Source:Jul 20, 2026, 01:41 UTC
Sunshine Lake Pharma's self-developed insulin glargine injection received FDA approval for marketing in the United States.
Source: